Related Experiment Video

Updated: Jul 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary

Leonie Strobbe1, Peter Lestrade, Mirjam H A Hermans

  • 1Department of Internal Medicine, Jeroen Bosch Hospital, 5200 ME, 's-Hertogenbosch, The Netherlands. leoniestrobbe@hotmail.com

Annals of Hematology
|August 19, 2007
PubMed

Insights

The Janus kinase 2 (JAK2V617F) mutation was found in 33% of patients with unexplained elevated blood counts. Many of these patients experienced thrombosis, suggesting a latent myeloproliferative disorder.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The Janus kinase 2 (JAK2V617F) mutation is linked to myeloproliferative disorders (MPDs).
  • MPDs are characterized by overproduction of blood cells, including platelets and red blood cells.
  • The JAK2V617F mutation's role in patients not meeting MPD diagnostic criteria is not fully understood.

Purpose of the Study:

  • To investigate the prevalence of the JAK2V617F mutation in patients with unexplained elevated platelet or hemoglobin levels.
  • To determine if the JAK2V617F mutation is associated with thrombosis in this patient group.
  • To explore the potential existence of latent MPDs.

Main Methods:

  • Screening for the JAK2V617F mutation using molecular assays.
  • Retrospective analysis of patient data, including blood counts and history of thrombosis.
  • Comparison of mutation status with clinical characteristics.

Main Results:

  • The JAK2V617F mutation was detected in 6 out of 18 patients (33%) with unexplained thrombocytosis or erythrocytosis.
  • Five of the six JAK2V617F-positive patients had a history of thrombosis.
  • No patients met the full diagnostic criteria for polycythemia vera or essential thrombocythemia.

Conclusions:

  • The JAK2V617F mutation may contribute to thrombosis through mechanisms other than overt thrombocytosis or erythrocytosis.
  • A subset of patients with unexplained elevated blood counts may have a latent form of MPD.
  • Further research is needed to clarify the clinical implications and optimal treatment strategies for these patients.

More Related Videos

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...